title: Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin.
authors.forename: Moises
authors.initials: M
authors.lastname: Diago
authors.forename: Tarek
authors.initials: T
authors.lastname: Hassanein
authors.forename: Juan
authors.initials: J
authors.lastname: Rodés
authors.forename: Andrew M
authors.initials: AM
authors.lastname: Ackrill
authors.forename: Farhad
authors.initials: F
authors.lastname: Sedarati
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D006526:Hepatitis C / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a